What level of vision do you need to access emerging IRD treatments?
The level of vision needed for a person to be included in a clinical trial of an emerging inherited retinal disease (IRD) treatment varies, depending on the intervention. The good news is that there are treatments being developed for all levels of vision.
In general, treatments like gene therapy are targeted at those with more remaining vision (i.e. earlier disease). This is because the gene therapy requires there to be residual photoreceptor cells in the retina to treat.
In comparison, treatment strategies like stem cells, optogenetics and vision prostheses (bionic eyes) may be options for people with very little or no vision left, as they are not as reliant on remaining photoreceptor cells.
All of these treatments (with the exception of Luxturna® gene therapy) are still experimental, and not widely accessible. Your ophthalmologist is the best person to give advice on what clinical trials, if any, may be suitable for your condition.